|Day Low/High||14.38 / 14.96|
|52 Wk Low/High||6.96 / 25.00|
-Presentation Includes Newly Reported Objective Response Rate and Patient Baseline Characteristics from HALO-202-
Lion Biotechnologies, XBiotech and Halozyme Therapeutics were among the biotech movers in premarket trading on Friday.
-HALO-202 Study Met Primary, Key Secondary Endpoints and Demonstrated a Statistically Significant Improvement in Progression-Free Survival (PFS) in Patients with High Levels of Hyaluronan-
Here's how to potentially rake in some fat profits off a number of hot breakout setups.
Halozyme Therapeutics, Omeros and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
The market response to the Fed was quite extreme, although there really wasn't any major development.
Jim Cramer interviews CEOs from Constellation and Halozyme about their businesses and their stocks' wild ride.
Jim Cramer says this rally relies on a speedy end to regulation, fast repatriation of foreign money and corporate tax reform.
-Study shows statistically significant improvement in progression-free survival (PFS) in all evaluable patients and in patients with high levels of hyaluronan (HA), a potential new biomarker-
Investors in Halozyme Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.
In recent trading, shares of Halozyme Therapeutics Inc have crossed above the average analyst 12-month target price of $13.15, changing hands for $13.83/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Phase 1b/2 studies will evaluate Halozyme's investigational drug, PEGPH20 with Genentech's anti-PDL1 Tecentriq® (atezolizumab)